Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia

Pharmacological Research

Volumn 52, Issue 6, 2005, Pages 497-501

  D'Arrigo, Concetta ^a   Migliardi, Gaetana ^a   Santoro, Vincenza ^a   Morgante, Letterio ^b   Muscatello, Maria Rosaria ^b   Ancione, Maria ^c   Spina, Edoardo ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c USL 5   (Italy)

Author keywords

9 Hydroxyrisperidone; CYP2D6; CYP3A4; Drug interaction; Fluvoxamine; Risperidone

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; FLUVOXAMINE; PALIPERIDONE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; MENTAL PATIENT; NAUSEA; NEGATIVE SYNDROME; POSITIVE SYNDROME; PRIORITY JOURNAL; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; FLUVOXAMINE; HUMANS; MALE; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA; SEROTONIN UPTAKE INHIBITORS;

EID: 27644480931     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2005.09.005     Document Type: Article

References (36)

1. G. Chouinard, and W. Arnott Clinical review of risperidone Can J Psychiatry 38 Suppl. 3 1993 89 95
2. S. Brunelleschi, P. Zeppegno, F. Risso, C.I. Cattaneo, and E. Torre Risperidone-associated hyperprolactinemia: evaluation in twenty psychiatric outpatients Pharmacol Res 48 2003 405 409
3. G. Mannens, M.L. Huang, W. Meuldermans, J. Hendrickx, R. Woestenborghs, and J. Heykants Absorption, metabolism and excretion of risperidone in humans Drug Metab Dispos 21 1993 1134 1141
4. M.L. Huang, A. van Peer, R. Woestenborghs, R. De Coster, J. Heykants, and A.A. Jansen Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects Clin Pharmacol Ther 54 1993 257 268
5. M.G. Scordo, E. Spina, G. Facciolà, A. Avenoso, I. Johansson, and M.L. Dahl Cytochrome P450 2D6 genotype and steady-state plasma levels of risperidone and 9-hydroxyrisperidone Psychopharmacology 147 1999 300 305
6. J. Fang, M. Bourin, and G.B. Baker Metabolism of risperidone to 9-hydroxyrisperidone by human cytochrome P450 2D6 and 3A4 Naunyn-Schmiederberg's Arch Pharmacol 359 1999 147 151
7. N. Yasui-Furukori, M. Hidestrand, E. Spina, G. Facciolà, M.G. Scordo, and G. Tybring Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes Drug Metab Dispos 29 2001 1263 1268
8. A.A. Megens, F.H. Awouters, A. Schotte, T.F. Meert, C. Dugovic, and C.J. Niemegeers Survey on pharmacodynamics of the new antipsychotic risperidone Psychopharmacology 114 1994 9 23
9. C.L. DeVane, and C.B. Nemeroff An evaluation of risperidone drug interactions J Clin Psychopharmacol 21 2001 408 416
10. E. Spina, A. Avenoso, G. Facciolà, M.G. Scordo, M. Ancione, and A. Madia Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine Ther Drug Monit 23 2001 223 227
11. E. Spina, A. Avenoso, M.G. Scordo, M. Ancione, A. Madia, and G. Gatti Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction J Clin Psychopharmacol 22 2002 419 423
12. G. Bondolfi, C.B. Eap, G. Bertschy, D. Zullino, A. Vermeulen, and P. Baumann The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients Pharmacopsychiatry 35 2002 50 56
13. M.I. Wilde, G.L. Plosker, and P. Benfield Fluvoxamine: an updated review of its pharmacology, and therapeutic use in depressive illness Drugs 46 1993 895 924
14. H. Silver Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms in schizophrenia Int Clin Psychopharmacol 18 2003 305 313
15. H.K. Crewe, M.S. Lennard, G.T. Tucker, F.R. Woods, and R.E. Haddock The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes Br J Clin Pharmacol 34 1992 262 265
16. K. Brosen, E. Skielbo, B.B. Rasmussen, H.E. Poulson, and S. Loft Fluvoxamine is a potent inhibitor of cytochrome P4501A2 Biochem Pharmacol 45 1993 1211 1214
17. Z.H. Xu, H.G. Xie, and H.H. Zhoou In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine Br J Clin Pharmacol 42 1996 518 521
18. J. Schmider, D.J. Greenblatt, L.L. von Moltke, D. Karsov, and R.I. Shader Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylaton Br J Clin Pharmacol 44 1997 495 498
19. M.U. Shad, and S.H. Preskorn Antidepressants R.H. Levy K.E. Thummel W.F. Trager P.D. Hansten M. Eichelbaum Metabolic drug interactions 2000 Lippincott Williams & Wilkins Philadelphia 563 577
20. E. Spina, M.G. Scordo, and C. D'Arrigo Metabolic drug interactions with new psychotropic agents Fundam Clin Pharmacol 17 2003 517 538
21. G.M. Simpson, and JW.S. Angus Drug-induced extrapyramidal disorders Acta Psychiatr Scand 212 Suppl. 1970 11 19
22. A. Avenoso, G. Facciolà, M. Salemi, and E. Spina Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection J Chromatogr B 746 2000 173 181
23. R.B. Ostroff, and J.C. Nelson Risperidone augmentation of selective serotonin reuptake inhibitors in major depression J Clin Psychiatry 60 1999 256 259
24. C.J. McDougle, C.N. Epperson, G.H. Pelton, S. Wasylink, and L.H. Price A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder Arch Gen Psychiatry 57 2000 794 801
25. R.M. Lane Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors Int Clin Psychopharmacol 11 Suppl. 5 1996 31 61
26. E. Spina, C. D'Arrigo, and G. Migliardi Plasma risperidone concentrations during combined treatment with sertraline Ther Drug Monit 26 2004 386 390
27. A. Avenoso, G. Facciolà, M.G. Scordo, C. Gitto, G. Drago Ferrante, and A. Madia No effect of citalopram on plasma levels of clozapine, risperidone and their active metabolites in patients with chronic schizophrenia Clin Drug Invest 16 1998 393 398
28. E. Spina, A. Avenoso, M.G. Scordo, M. Ancione, A. Madia, and A. Levita No effect of reboxetine on plasma concentrations of clozapine, risperidone and their active metabolites Ther Drug Monit 23 2001 675 678
29. R. Zoccali, M.R. Muscatello, D. La Torre, G. Malara, A. Canale, and D. Crucitti Lack of pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia Pharmacol Res 48 2003 411 414
30. C.L. Alfaro, Y.W. Lam, J. Simpson, and L. Ereshefsky CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline J Clin Psychopharmacol 19 1999 155 163
31. E. Spina, A.M. Pollicino, A. Avenoso, G.M. Campo, A.P. Caputi, and E. Perucca Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects Ther Drug Monit 15 1993 243 246
32. D.G. Daniel, C. Randolph, G. Jaskiw, S. Handel, T. Williams, and A. Abi-Dargham Coadministration of fluvoxamine increases serum concentrations of haloperidol J Clin Psychopharmacol 14 1994 340 343
33. M. Jerling, L. Lindstrom, U. Bondesson, and L. Bertilsson Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service Ther Drug Monit 16 1994 368 374
34. C. Hiemke, H. Weighmann, S. Hartter, N. Dahmen, H. Wetzel, and H. Muller Elevated serum levels of clozapine after addition of fluvoxamine J Clin Psychopharmacol 14 1994 279 281
35. C. Hiemke, P. Avi, M. Jabarin, J. Hadjez, H. Weigmann, and S. Hartter Fluvoxamine augmentation of olanzapine in chronic schizophrenia :pharmacokinetic interactions and clinical effects J Clin Psychopharmacol 22 2002 502 506
36. E. Spina, A. Avenoso, G. Facciolà, M. Salemi, M.G. Scordo, and M. Ancione Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia Psychopharmacology 153 2001 238 243